経口ドラッグデリバリーシステム市場：タイプ、用途、エンドユーザー別-2025-2030年の世界予測

経口ドラッグデリバリーシステム市場は、2023年に22億3,000万米ドルと評価され、2024年には24億3,000万米ドルに達すると予測され、CAGR 9.34％で成長し、2030年には41億8,000万米ドルに達すると予測されています。

経口ドラッグデリバリーシステムでは、口腔粘膜を通して薬物を投与することで、従来の経口および非経口経路に代わる有利な選択肢としています。この方法は、消化管での分解や初回通過代謝をバイパスすることで薬物のバイオアベイラビリティを向上させるため、初回通過効果の大きい薬物や消化管環境で不安定な薬物にとって極めて重要です。その用途は、疼痛管理、ホルモン療法、禁煙、心血管疾患など、治療分野にまたがっています。エンドユーザーは主に病院、クリニック、在宅ヘルスケア環境です。市場成長の原動力となっているのは、高齢者人口の増加、慢性疾患の蔓延、非侵襲的ドラッグデリバリー法への継続的需要です。生体接着性ポリマーやナノテクノロジーなど、製剤科学における技術の進歩が新たな機会をもたらしています。しかし、薬物負荷容量の制限、口腔粘膜への潜在的刺激、味のマスキングに関する問題などの課題は、市場の成長を抑制する可能性があります。また、規制基準や高い競合も主要な障壁となっています。今後のビジネスチャンスを生かすために、企業は革新的な製剤技術の開発、より良い味と剤形の美しさによる患者のコンプライアンスの向上、技術進歩のためのパートナーシップの模索に注力すべきです。個別化医療と生物製剤への注目の高まりは、患者固有のニーズに合わせた頬部システムのさらなる可能性を開くものです。研究開発は、薬物吸収率の向上と新たな治療領域の開拓を優先すべきです。市場は複雑だが、ヘルスケアの効率化要求と患者中心のケアモデルによって、この分野は引き続き成長する態勢にあります。企業は包括的な市場調査に投資し、ダイナミックな市場動向と患者のニーズを把握することで、競争力を維持し、潜在的なニッチを開拓すべきです。患者からのフィードバックや市場のモデル化のためにデジタル技術を取り入れることで、ソリューションをさらにカスタマイズし、既存の市場やアプリケーションの限界に効果的に対処することができると思われます。

市場力学：急速に進化する経口ドラッグデリバリーシステム市場の主要市場インサイトを公開

経口ドラッグデリバリーシステム市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 薬剤投与と終了の容易さによる高い嗜好性
  • 高齢者人口の増加に伴う慢性疾患の流行
  • 世界の医薬品開発需要の増加
• 市場抑制要因
  • 大量投与が困難
• 市場機会
  • 経口投与のためのナノ粒子ドラッグデリバリーアプローチの進歩
  • 頬粘膜粘着性錠剤の開発
• 市場の課題
  • 唾液内に薬剤が偏在しないことによる患者の受容性の問題

ポーターの5つの力：経口ドラッグデリバリーシステム市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：経口ドラッグデリバリーシステム市場における外部からの影響の把握

外部マクロ環境要因は、経口ドラッグデリバリーシステム市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析経口ドラッグデリバリーシステム市場における競合情勢の把握

経口ドラッグデリバリーシステム市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス経口ドラッグデリバリーシステム市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、経口ドラッグデリバリーシステム市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨経口ドラッグデリバリーシステム市場における成功への道筋を描く

経口ドラッグデリバリーシステム市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 薬剤投与と投与終了の容易さによる高い好感度
    • 慢性疾患の蔓延と高齢者人口の増加
    • 世界の医薬品開発の需要増加
  • 抑制要因
    • 大量投与の困難
  • 機会
    • 口腔内投与のためのナノ粒子ドラッグデリバリーアプローチの進歩
    • 口腔粘膜付着性錠剤の開発
  • 課題
    • 唾液中の非普遍的な薬物分布に対する患者の受容性に関する問題
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 経口ドラッグデリバリーシステム市場：タイプ別

• バッカル錠
• 経口スプレー
• 舌下フィルム

第7章 経口ドラッグデリバリーシステム市場：用途別

• 狭心症
• 疼痛管理
• 禁煙

第8章 経口ドラッグデリバリーシステム市場：エンドユーザー別

• 外来センター
• 病院

第9章 南北アメリカの経口ドラッグデリバリーシステム市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の経口ドラッグデリバリーシステム市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの経口ドラッグデリバリーシステム市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 3M Company
• Amgen Inc.
• Aquestive Therapeutics, Inc.
• ARx, LLC
• AstraZeneca Plc
• Camurus
• Catalent, Inc.
• Cure Pharmaceutical
• DuPont de Nemours, Inc.
• Generex Biotechnology
• Herantis Pharma PLC
• Indivior PLC
• LTS Lohmann Therapie-Systeme AG
• MedLab Clinical Ltd
• Nektar Therapeutics
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Sorrento Therapeutics, Inc.
• Tesa Labtec GmbH
• Vectura Group

LIST OF FIGURES

• FIGURE 1. BUCCAL DRUG DELIVERY SYSTEMS MARKET RESEARCH PROCESS
• FIGURE 2. BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BUCCAL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BUCCAL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BUCCAL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BUCCAL DRUG DELIVERY SYSTEMS MARKET DYNAMICS
• TABLE 7. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUCCAL TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL SPRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBLINGUAL FILMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANGINA PECTORIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SMOKING CESSATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. CANADA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. CHINA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. ITALY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ITALY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. POLAND BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. POLAND BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. QATAR BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. QATAR BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. BUCCAL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. BUCCAL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2023

The Buccal Drug Delivery Systems Market was valued at USD 2.23 billion in 2023, expected to reach USD 2.43 billion in 2024, and is projected to grow at a CAGR of 9.34%, to USD 4.18 billion by 2030.

Buccal Drug Delivery Systems involve administering drugs through the mucosal lining of the oral cavity, serving as an advantageous alternative to traditional oral and parenteral routes. This method enhances drug bioavailability by bypassing gastrointestinal tract degradation and first-pass metabolism, making it crucial for drugs with significant first-pass effect or those unstable in the gastrointestinal environment. Applications span across therapeutic areas, including pain management, hormone therapy, smoking cessation, and cardiovascular diseases. End-users primarily consist of hospitals, clinics, and home healthcare settings. Market growth is fueled by the expanding geriatric population, increasing prevalence of chronic diseases, and the continuous demand for non-invasive drug delivery methods. Technological advancements in formulation science, such as bioadhesive polymers and nanotechnology, present emerging opportunities. However, challenges like limited drug load capacity, potential irritation of the oral mucosa, and issues related to taste masking can restrain market growth. Regulatory standards and high competition are also key barriers. To capitalize on upcoming opportunities, companies should focus on developing innovative formulation techniques, improving patient compliance through better taste and dosage form aesthetics, and exploring partnerships for technology advancement. The increasing focus on personalized medicine and biologics opens further avenues for buccal systems tailored to patient-specific needs. R&D should prioritize enhancing drug absorption rates and exploring new therapeutic areas. Despite market complexities, the sector remains poised for growth, driven by healthcare efficiency demands and patient-centric care models. Companies should invest in comprehensive market research to understand dynamic market trends and patient needs, maintaining competitiveness and tapping into potential niches. Embracing digital technologies for patient feedback and market modelling could further customize solutions and address existing market and application limitations effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Buccal Drug Delivery Systems Market

The Buccal Drug Delivery Systems Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • High preferences due to ease of drug administration and termination
  • Prevalence of chronic diseases coupled with growth in geriatric population
  • Increased demand for drug development globally
• Market Restraints
  • Difficulty in administration of large doses
• Market Opportunities
  • Advances in nanoparticulate drug delivery approaches for buccal administration
  • Developments in buccal mucoadhesive tablets
• Market Challenges
  • Issues with patient acceptability for non ubiquitous drug distribution within saliva

Porter's Five Forces: A Strategic Tool for Navigating the Buccal Drug Delivery Systems Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Buccal Drug Delivery Systems Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Buccal Drug Delivery Systems Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Buccal Drug Delivery Systems Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Buccal Drug Delivery Systems Market

A detailed market share analysis in the Buccal Drug Delivery Systems Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Buccal Drug Delivery Systems Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Buccal Drug Delivery Systems Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Buccal Drug Delivery Systems Market

A strategic analysis of the Buccal Drug Delivery Systems Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Buccal Drug Delivery Systems Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Amgen Inc., Aquestive Therapeutics, Inc., ARx, LLC, AstraZeneca Plc, Camurus, Catalent, Inc., Cure Pharmaceutical, DuPont de Nemours, Inc., Generex Biotechnology, Herantis Pharma PLC, Indivior PLC, LTS Lohmann Therapie-Systeme AG, MedLab Clinical Ltd, Nektar Therapeutics, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sorrento Therapeutics, Inc., Tesa Labtec GmbH, and Vectura Group.

Market Segmentation & Coverage

This research report categorizes the Buccal Drug Delivery Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Buccal Tablets, Oral Sprays, and Sublingual Films.
• Based on Application, market is studied across Angina Pectoris, Pain Management, and Smoking Cessation.
• Based on End-user, market is studied across Ambulatory Centers and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. High preferences due to ease of drug administration and termination
    • 5.1.1.2. Prevalence of chronic diseases coupled with growth in geriatric population
    • 5.1.1.3. Increased demand for drug development globally
  • 5.1.2. Restraints
    • 5.1.2.1. Difficulty in administration of large doses
  • 5.1.3. Opportunities
    • 5.1.3.1. Advances in nanoparticulate drug delivery approaches for buccal administration
    • 5.1.3.2. Developments in buccal mucoadhesive tablets
  • 5.1.4. Challenges
    • 5.1.4.1. Issues with patient acceptability for non ubiquitous drug distribution within saliva
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Buccal Drug Delivery Systems Market, by Type

• 6.1. Introduction
• 6.2. Buccal Tablets
• 6.3. Oral Sprays
• 6.4. Sublingual Films

7. Buccal Drug Delivery Systems Market, by Application

• 7.1. Introduction
• 7.2. Angina Pectoris
• 7.3. Pain Management
• 7.4. Smoking Cessation

8. Buccal Drug Delivery Systems Market, by End-user

• 8.1. Introduction
• 8.2. Ambulatory Centers
• 8.3. Hospitals

9. Americas Buccal Drug Delivery Systems Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Buccal Drug Delivery Systems Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Buccal Drug Delivery Systems Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 3M Company
• 2. Amgen Inc.
• 3. Aquestive Therapeutics, Inc.
• 4. ARx, LLC
• 5. AstraZeneca Plc
• 6. Camurus
• 7. Catalent, Inc.
• 8. Cure Pharmaceutical
• 9. DuPont de Nemours, Inc.
• 10. Generex Biotechnology
• 11. Herantis Pharma PLC
• 12. Indivior PLC
• 13. LTS Lohmann Therapie-Systeme AG
• 14. MedLab Clinical Ltd
• 15. Nektar Therapeutics
• 16. Novartis AG
• 17. Novo Nordisk A/S
• 18. Pfizer Inc.
• 19. Sorrento Therapeutics, Inc.
• 20. Tesa Labtec GmbH
• 21. Vectura Group